BBIO icon

BridgeBio Pharma

28.53 USD
+0.76
2.74%
At close Dec 24, 4:00 PM EST
After hours
27.99
-0.54
1.89%
1 day
2.74%
5 days
2.33%
1 month
4.93%
3 months
14.76%
6 months
24.04%
Year to date
-29.47%
1 year
-32.06%
5 years
-37.30%
10 years
3.56%
 

About: BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Employees: 556

0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

317% more call options, than puts

Call options by funds: $288M | Put options by funds: $68.9M

43% more repeat investments, than reductions

Existing positions increased: 103 | Existing positions reduced: 72

8% more funds holding in top 10

Funds holding in top 10: 12 [Q2] → 13 (+1) [Q3]

3% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 39

0% more funds holding

Funds holding: 248 [Q2] → 249 (+1) [Q3]

2% less capital invested

Capital invested by funds: $4.46B [Q2] → $4.36B (-$100M) [Q3]

3.01% less ownership

Funds ownership: 94.19% [Q2] → 91.18% (-3.01%) [Q3]

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$45
58%
upside
Avg. target
$48
67%
upside
High target
$50
75%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Evercore ISI Group
Cory Kasimov
20% 1-year accuracy
3 / 15 met price target
75%upside
$50
Outperform
Maintained
23 Dec 2024
HC Wainwright & Co.
Raghuram Selvaraju
38% 1-year accuracy
118 / 313 met price target
72%upside
$49
Buy
Reiterated
16 Dec 2024
Scotiabank
Greg Harrison
33% 1-year accuracy
9 / 27 met price target
68%upside
$48
Sector Outperform
Maintained
25 Nov 2024
B of A Securities
Geoff Meacham
32% 1-year accuracy
8 / 25 met price target
58%upside
$45
Buy
Maintained
25 Nov 2024
Leerink Partners
Mani Foroohar
25% 1-year accuracy
4 / 16 met price target
61%upside
$46
Outperform
Maintained
17 Oct 2024

Financial journalist opinion

Based on 5 articles about BBIO published over the past 30 days

Neutral
GlobeNewsWire
1 week ago
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union (EU) for acoramidis for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered near-complete (≥90%) transthyretin (TTR) stabilizer. ATTR-CM is a progressive fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. In the Phase 3 study ATTRibute-CM, acoramidis showed clear benefits on cardiovascular outcomes.
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Neutral
GlobeNewsWire
3 weeks ago
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech developing orally-delivered macrocyclic peptides to address previously undruggable targets, announced today that BridgeBio Pharma, Inc. (Nasdaq: BBIO), has exercised its option to license macrocyclic peptide candidates discovered using UNP's AI-enabled massively parallel chemistry platform.
Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Development in Rare Diseases and Oncology
Positive
Zacks Investment Research
4 weeks ago
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
Positive
Investors Business Daily
4 weeks ago
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted.
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
Positive
Benzinga
4 weeks ago
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
On Friday, the FDA approved BridgeBio Pharma, Inc.'s BBIO Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM to reduce cardiovascular death and cardiovascular-related hospitalization.
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
Positive
Seeking Alpha
1 month ago
BridgeBio: Next Chapter Begins After Attruby Approval
BridgeBio announced the FDA approval of Attruby (acoramidis) for the treatment of patients with ATTR-CM. The label looks clean and it includes all the relevant clinical data. Attruby's approval also triggers a $500 million milestone payment to BridgeBio under the royalty-backed deal it signed earlier this year and removes a regulatory and funding overhang on the stock.
BridgeBio: Next Chapter Begins After Attruby Approval
Positive
Reuters
1 month ago
US FDA approves BridgeBio's drug for rare heart condition
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said on Friday, making it the first new treatment in a market dominated by Pfizer's blockbuster Vyndaqel.
US FDA approves BridgeBio's drug for rare heart condition
Neutral
GlobeNewsWire
1 month ago
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
Positive
Benzinga
1 month ago
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
On Monday, BridgeBio Pharma, Inc.  BBIO presented initial outcomes from the ATTRibute-CM open-label extension (OLE) study of acoramidis in ATTR-CM at the American Heart Association Scientific Sessions.
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
Neutral
GlobeNewsWire
1 month ago
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
- Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
Charts implemented using Lightweight Charts™